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tional myeloablative, targeted dose of IV BU (16 doses),
reduced dose of CY (105 mg/kg), Fludarabine (FLU) 140 mg/
m2, and Alemtuzumab 52mg/m2 total pre-transplant in 3
doses. GVHD prophylaxis consisted of alemtuzumab 10mg/
m2 on Days+1 and +2, cyclosporine (or tacrolimus), and
mycophenolate mofetil. All patients engrafted and survive
without severe GVHD. The prolonged immune deﬁciency
with intensive alemtuzumab was complicated by a high risk
of viral infection, requiring both intensive antiviral prophy-
laxis and treatment. We conclude that this regimen signiﬁ-
cantly decreases immediate post-transplant morbidity,
maintains engraftment potential, and decreases the risk of
GVHD. The use of FLU and intensive alemtuzumab condi-
tioning to permit decreased CY dosing, along with post-
transplant alemtuzumab, can overcome the major obstacles
(TRM, non-engraftment, GVHD) to successful HCT for
patients with genetic diseases lacking a conventional donor.
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Background: Acute leukemias (ALL or AML) in third
complete remission (CR3), refractory relapse (RR) or induc-
tion failure (IF) have an extremely poor prognosis, with<20%
event free survival (EFS) (Gaynon, BJH, 2005; Wells, JCO,
2003). CLO, an inhibitor of DNA polymerase and ribonucle-
otide reductase, has been shown to be safe and induce
durable remissions, both in conjunction with busulfan in
poor-risk AML (Magenau et al., Blood, 2011) and with
Melphalan in poor-risk hematologic malignancies in adults
(van Besien et al, BBMT, 2012). Clo has also been found to
have signiﬁcant activity in relapsed ALL and AML (Jeha, JCO
2006, 2009) and synergy with cytarabine (Faderl, Blood,
2005). We therefore sought to determine safety, day-100
TRM, and overall survival (OS) associated with CLO, cytar-
abine and TBI followed by AlloSCT in CAYAwith poor-risk ALL
or AML.
Methods: This is a multi-center phase I/II trial of a novel
conditioning regimen of CLO (dose escalation; maximal dose
of 52mg/m2/d achieved without dose limiting toxicity) x5d,
sequential (4 hrs later) cytarabine 1000 mg/m2 x6d and TBI
(1200cGy) followed by AlloSCT from matched related or
unrelated donors in CAYA with ALL or AML in CR3, RR or IF.Patients with unrelated donors received R-ATG. GVHD
prophylaxis consisted of tacrolimus and MMF (Bhatia/Cairo,
BBMT, 2009). Kaplan-Meier method was used to determine
the probabilities of engraftment, GVHD, TRM and OS.
Results: 29 pts, median age: 11.8 yrs (1.5-21); M:F: 20:9, ALL/
AML: 26:3 (10 CR3, 3 RR, 16 IF), 10 related donors, 19 unre-
lated donors (11 BM/PBSCs, 8 UCB). Median TNC and CD34
dose was 4.51x108/kg and 4.8 x106/kg for BM/PBSCs and
4.24x107/kg and 3.4x105/kg for UCB, respectively. Probabili-
ties of neutrophil, platelet engraftment, grade II-IV aGVHD
and chronic GVHD were 100%, 93%, 45%, and 35%, respec-
tively. Probability of Day 100 TRM was only 7.6%. The prob-
ability of relapse was 27% (CI95: 4-59%). Probability of 1-yr
PFS and OS were 52% (CI95: 30-70%), and 46% (CI95: 26-64%)
respectively.
Conclusions: These updated results suggest that this novel
conditioning regimen followed by AlloSCT is safe and well
tolerated in CAYA with very poor-risk ALL or AML with CLO
dose 52 mg/m2. Our results also continue to be encouraging
with respect to a low risk of day 100 TRM and leukemic
relapse rate associated with this conditioning regimen in this
poor-risk population. This approach should be considered in
better risk patients with ALL/AML who require AlloSCT.279
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Overview: pBKV (10,000 copies/ml) after kidney transplant
is associated with kidney injury. We hypothesized that pBKV
contributes to lower day 100 estimated kidney function
(eGFR) post-SCT.
Methods: Retrospective cohort analysis of 100 SCT recipients
prospectively enrolled to study thrombotic microangiopathy
(TMA). Plasma BK PCR testing was performed for hematuria
or elevated creatinine (creat) or on stored samples in those
with no clinical indication. We included allogeneic SCTs with
1 BK plasma PCR from each of day: 0-14, 15-85, and
10014. The outcome was day 100 eGFR using serum cys-
tatin C (cysC, muscle mass-independent eGFR) and creat.
pBKV was deﬁned as 4 consecutive weekly PCRs 10,000
copies/ml. We tested associations between pBKV and clinical
data, laboratory results, and medication exposures (coded
yes/no in ﬁrst 100 days). Multivariate regression assessed
eGFR, pBKV, and covariates with a univariate P < .2.
Results: Of 72 included subjects, 7 (10%) had pBKV and 65
(90%) did not: 7/65 had transient BKV 10,000 copies/ml on
a median of 2 measures. Selected univariate risk factors for
pBKV are shown in the Table 1. There was no difference in
age, sex, diagnosis, pre-SCT nuclear GFR, total body irradia-
tion, acute GVHD, steroid prophylaxis, cyclosporine level,
VOD, grade 2 cystitis, CMV, adenoviremia, or dialysis. By
univariate analyses, the pBKV group had signiﬁcantly lower
day 100 cysC, but not creat-based eGFR (Table 1) and more
likely received cidofovir (P < .0001). On multivariable anal-
yses, T-cell modulating antibody therapy trended (P ¼ .13)
towards an associationwith pBKV. pBKVwas associated with
Table 1
Persistent BK
viremia n¼7
No persistent
viremia n¼65
P-value*
Age, years 6 (3-19) 8 (2-14) 0.57
Reduced intensity vs
myeloablative
71% 38% 0.12
Un-related donor
vs related
100% 71% 0.18
Fludarabine prep 86% 49% 0.11
Alemtuzumab prep 71% 37% 0.11
T-cell modulating
antibody
GVHD therapy
43% 12% 0.07
TMA 71% 37% 0.11
Pre-SCT nuclear GFR 111 (105-139) 122 (104-144) 0.64
Day 100 eGFR equations
CysC
Zappitelli 55 (42-64) 83 (62-103) 0.02
Rule 46 (35-55) 73 (53-93) 0.02
CKiD cysC 54 (44-62) 76 (60-90) 0.02
Creat
Bedside CKiD 104 (68-116) 100 (83-122) 0.86
CysC and creat
Full CKiD 68 (64-78) 89 (72-97) 0.06
Data as median (25th-75th percentile) or %.
GFR in ml/min/1.73m2, normal >90.
CKiD, Chronic Kidney Disease in Children study.
* Mann-Whitney U or Fischer exact.
Table 1
Reduce Intensity Conditioning for Marrow failure disorders
Characteristics Number (%)/
Median (range)
Total number of patients 22
Diagnosis
Shwachman-diamond syndrome 8
Aplastic anemia/marrow failure syndrome 7
Dyskeratosis Congenita 3
Seckel syndrome 1
Kostmann’s syndrome 1
Sideroblastic anemia 1
Congenital Macrothrombocytopenia 1
Age in years at HCT 7.27(0.7 -27)
Donor source
MSD 6
URD 15
UR cord 1
Stem cell source
Marrow 20
PBSC 1
Cord 1
Time to neutrophil engraftment (days) 12 (10-48)
Mixed chimerism 1
Resolved 1
GVHD
Acute GVHD (Gr II-III) 3
Chronic GVHD (skin) 3
Overall outcome
Alive 18
Deceased 4
Causes of and post-transplant day of death
Liver failure 668
Disseminated fungal infection 264
Coccidoidomycosis 35
Multiorgan failure 154
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adjusting for cidofovir.
Conclusions: T-cell modulating antibody therapy may be
a risk factor for BKV. pBKV possibly contributes to lower day
100 cysC eGFR, but we are unable to conclude an indepen-
dent association as most with pBVK also received nephro-
toxic cidofovir. Creat-based eGFR was no different, perhaps
because of low muscle mass after SCT. Future studies will
follow-up past day 100, temporally assess covariates (cido-
fovir), and uniformly measure BKV exposure in all subjects.
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Background: Hematopoietic cell transplantation (HCT)
remains the only potentially curative option for majority of
the inherited marrow failure syndromes and for patients
with aplastic anemia who don't respond to immune
suppression. It is challenging to rule out inherited marrow
failure syndromes with certainty in patients who present
with pancytopenia at very young age, with the possibility of
them carrying yet unidentiﬁed genetic mutation/s. This in
turn makes it difﬁcult to treat them similar to patients with
idiopathic aplastic anemia or using myeloablative prepara-
tive regimens/regimens containing total body irradiation(TBI). The inherent chemotherapy and radiation sensitivity of
some of the congenital marrow failure syndromes (e.g.
Shwachman-diamond syndrome (SDS), Dyskeratosis Con-
genita (DC)) leads to increased toxicity with intensive
conditioning regimens. Here we report our experience with
reduced intensity preparative regimen for Non-Fanconi
anemia marrow failure syndromes.
Methods: Total twenty two Non-FA marrow failure
syndromes and/or aplastic anemia patients were trans-
planted using a RIC regimen containing alemtuzumab, ﬂu-
darabine and Melphalan. Patients with Alemtuzumab doses
and schedules varied somewhat depending on size of the
patients (<10kg e got 0.2mg/kg/dose x 5 days) and on risk of
GVHD vs. mixed chimerism (alemtuzumab on days -22 to 18
vs from day -14 to 10). All patients received ﬂudarabine
30mg/M2 (1mg/kg if <10kg) on days -8 to -4, and melphalan
140mg/M2 (4.7mg/kg if <10kg) on day -3. Melphalan was
reduced by 50% in 3 patients with DC and 2 patients with
known chromosome sensitivity, due to concern for excessive
toxicity with full dose melphalan. GVHD prophylaxis con-
sisted of methylprednisolone and cyclosporine in all. Four-
teen patients additionally received methotrexate.
Results: Patient and transplant characteristics along with
results are shown in Table 1. Overall, one year probability of
survival was 84% with 95% conﬁdence interval of 67.0-100%.
This is a signiﬁcant improvement compared to historical
results. Eighteen patients are alive, well and remain 100%
engrafted at a median follow-up of 1.4 years (range 0.3-6.26).
Conclusion: We conclude that allogeneic HCT, using alem-
tuzumab, ﬂudarabine and melphalan-based reduced inten-
sity conditioning results in durable engraftment and an
excellent survival in pediatric patients with marrow failure
syndromes.
